Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.本發明敘述對抗癌症的胜肽疫苗。尤其，提供會誘出細胞毒殺性T淋巴球的來自UBE2T的抗原決定位胜肽。也提供有細胞毒殺性T淋巴球誘導能力的單離的抗原呈現細胞，及導向此種胜肽之細胞毒殺性T淋巴球，以及用於誘導此抗原呈現細胞或細胞毒殺性T淋巴球的方法。本發明也提供一種藥學組合物，其包含此種來自UBE2T之抗原結合位胜肽或編碼為此多胜肽之多核苷酸作為有效成分。又，本發明提供治療及/或預防(即防止)癌症(腫瘤)，及/或防止其術後再復發的方法，及誘導細胞毒殺性T淋巴球之方法、誘導抗腫瘤免疫性之方法，係使用來自UBE2T之抗原決定位胜肽、編碼為此胜肽之多核苷酸、或呈現此胜肽之抗原呈現細胞、或本發明之藥學組合物。
